Table 2 : Guidelines on the use of TA in clinical practice-evidence-based appraoch.

	German Working Group of Clinical Nephrology, 2002 [3]				Apheresis Applications Committee of the ASFA, 2010, 2013 [3, 6, 7]
	TA modality	Evidence class	Severity grade	TA modality		Category	Recommendation grade
RRGN (ANCA associated) dialysis dependence DAH Immune complex nephritis, dialysis- independence	TPE, IA-Protein-A, Peptid-GAM®	I b	A	TPE		I I III	1A 1C 2B
Anti-glomerular basement disease (Goodpasture´s syndrome), dialysis- dependent, no DAH DAH Dialysis-independent	TPE, IA-Protein-A, Peptid-GAM®	II a	B	TPE		III I I	2B 1C 1B
Focal segmental GN (FSGN) primary secondary recurrent (in transplanted kidney)	TPE, IA-Protein-A, Peptid-GAM®, Tryptophan, Anti-human-Ig	IV III ---	C B ---	TPE		III III I	--- --- IB